Association between swimming pool operator certification and reduced pool chemistry violations--Nebraska, 2005-2006.

Previous studies have recommended mandatory education for all public pool operators, but substantiating data are limited. This study evaluates associations between pool operator certification and chemistry violations by using 2005-2006 Nebraska routine pool inspection reports. Training and certification for nonmunicipal pool operators are only required in two Nebraska counties. Free chlorine violations for nonmunicipal pool inspections were compared in counties with and without certified operator requirements. To control for water supply pH, inspections from nonmunicipal pools with shared-source water in two counties (one requiring certification) were compared for concurrent pH and free chlorine violations. Compared with locations that require certified operators, free chlorine violations and concurrent pH and free chlorine violations were twice as likely in locations without certification. As a result, pools without required operator certification might pose greater health risks. These results demonstrate the benefit of requiring pool operator certification to help prevent recreational water illnesses.

Sensitivity of second-generation enzyme immunoassay for detection of hepatitis C virus infection among oncology patients.

BACKGROUND: The second-generation hepatitis C virus (HCV) enzyme immunoassay (EIA 2), an antibody-detection test, has high sensitivity and is one of the recommended screening tests for detecting HCV infection in the United States. However, its sensitivity among oncology patients is unknown. OBJECTIVE: Assess the EIA 2 sensitivity among a group of oncology patients at a Nebraska clinic where an HCV outbreak occurred during 2000-2001 using nucleic acid testing (NAT) and recombinant immunoblot assay (RIBA) as the gold standards. STUDY DESIGN: Serum specimens were collected from patients 16 months after transmission had stopped. We tested the specimens using EIA 2 (Abbott HCV EIA 2.0), a NAT assay based on transcription-mediated amplification (TMA) (Gen-Probe TMA assay) and RIBA (Chiron RIBA HCV 3.0 SIA). HCV infection was defined as a positive RIBA or TMA test in an oncology patient. Alanine aminotransferase (ALT) levels were determined in EIA 2-negative/TMA-positive samples. RESULTS: A total of 264 samples were included in the study. We identified 92 HCV infections, 76 of which were Abbott EIA 2 positive. Abbott EIA 2 sensitivity was 83% (76/92), lower than that reported among healthy adults (90%) (p=0.01) and poor sensitivity was associated with receipt of chemotherapy during the outbreak period (p=0.02). Only 1 (6%) of the 16 EIA 2-negative cases had elevated ALT. CONCLUSIONS: In this study, EIA 2 sensitivity among oncology patients was lower than that previously reported among immunocompetent persons. Impaired antibody production related to cancer and/or chemotherapy might explain the reduced sensitivity. These findings indicate that, when assessing HCV status in oncology patients, a NAT test should be routinely considered in addition to EIA.